Category Archives: Neuroblastomas

Crizotinib and children

Abstract 11509 covers 107 pediatric patients and their tumors. ALK alterations were found in 18 of them (not all are fusion mutations). The ages ranged from 3-16 years. 7 patients were still being treated at the data cut off. At … Continue reading

Posted in crizotinib - Xalkori from Pfizer, Glioblastomas, Neuroblastomas, Potential Treatments, Research, Side Effects | Leave a comment

New ALK inhibitor reported

According to the article summary, current ALK inhibitors do not inhibit the G1202R mutant of the ALK gene, which is one of the most common mutations. The researchers announced the development of a structural analogue of Alectinib (called JH-VIII-157-02) that … Continue reading

Posted in Brain metastases, Glioblastomas, JH-VIII-157-02, Lung cancer, Neuroblastomas, Potential Treatments, Research, Resistance to treatment | Leave a comment

Ignyta update

As of December 4, 2014, Ignyta has posted the following in a press release: “Entrectinib is currently in two Phase I/II clinical trials, the STARTRK-1 trial and the ALKA-372-001 trial. The company presented interim results from the ALKA-372-001 study in … Continue reading

Posted in Lung cancer, Neuroblastomas, RXDX-101 - entrectinib - by Ignyta | Leave a comment

Anti-ALK antibody research

The Ronan Thompson Foundation and Solving Kids’ Cancer award $80,000 grant to fund new therapeutic antibody research to treat children with neuroblastoma and other ALK+ cancers. The award of $80,000 was granted to the Children’s Hospital of Philadelphia (CHOP). Researchers … Continue reading

Posted in Glioblastomas, Neuroblastomas, Research | Leave a comment

Ignyta ASCO update for RXDX-101

11 patients with ALK+ treated (not all NSCLC). 7 patients with ROS1 treated. Treatment is an oral pill. The previous statement made about the treatment involving an IV infusion was wrong. However the fact that patients only received treatment for … Continue reading

Posted in Lung cancer, Neuroblastomas, Research, RXDX-101 - entrectinib - by Ignyta | Leave a comment

What causes ALK+ lung cancer?

Someone recently posted this question on Inspire.com. Here was my reply. I have wondered about this for a while. I recently found some information others may find interesting. I do not know if any of the following applies to ROS+ … Continue reading

Posted in Anaplastic Large-Cell Lymphomas, Lung cancer, Neuroblastomas, Research | Leave a comment

Treating Pediatric Cancers

Here is a link to an article about the surprising success of using Crizotinib to treat three pediatric cancers (anaplastic large cell lymphoma(ALCL), inflammatory myofibroblastic tumors, and neuroblastomas). For example, 88% of the treated ALCL Patients experienced a complete response … Continue reading

Posted in Anaplastic Large-Cell Lymphomas, Neuroblastomas, Potential Treatments | Leave a comment

ALK Antibodies

This post covers potential ALK Antibody treatments.

Posted in Neuroblastomas, Potential Treatments, Research | 3 Comments

Other Drugs

A place to post info on other potential drugs for which there is no specific page or for posting research that covers two or more different drugs.

Posted in Anaplastic Large-Cell Lymphomas, Glioblastomas, Lung cancer, Neuroblastomas, Potential Treatments, Research | Tagged | 23 Comments

Research on drugs from Teva (formerly Cephalon)

This page is for tracking research by Teva (formerly Cephalon), including CEP-37440, CEP-28122, CEP-14083, CEP-14513, and compound “15”. There are several research articles by Cephalon and they refer to different drugs using different names so it is unclear when different articles are talking about the same drug … Continue reading

Posted in Anaplastic Large-Cell Lymphomas, Neuroblastomas, Potential Treatments, Research | 12 Comments